Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy

Inclusion Criteria: * Age of 18-70 years (both inclusive) at the time of signing informed consent * Body mass index of 25.0-40.0 kg/m\^2 (both inclusive) * Subject diagnosed (clinically) with type 2 diabetes mellitus for at least 180 days prior to the day of screening * Insulin naïve subject; however, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes Exclusion Criteria: * Known or suspected hypersensitivity to the trial products or related products * Any disorder which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol * Presence of clinically significant gastrointestinal disorders potentially affecting absorption of drugs and/or nutrients, as judged by the investigator